

Cleansing Notice

Pro-rata non-renounceable entitlement offer

23 July 2020, Melbourne: This notice is given by Rhythm Biosciences Limited (RHY or the Company).

This notice is given in accordance with section 708AA(2)(f) of the Corporations Act 2001 (Cth) (Corporations Act), as modified by Australian Securities and Investment Commission's Corporations (Non-Traditional Rights Issues) Instrument 2016/84 (Legislative Instrument).
Background

The Company has today announced that it is undertaking a pro-rata non renounceable entitlement offer to raise up to approximately \$3.6 million (before costs) (Entitlement Offer). Under the Entitlement Offer, eligible shareholders with a registered address in Australian and New Zealand will be invited to subscribe for 3 fully paid ordinary share (New Shares) for every 5 existing shares in the Company held as at 7pm (Melbourne time) on 28 July 2020 at an issue price of \$0.06 per New Share.

The Entitlement Offer is not underwritten however the Company has accepted an aggregate of up to \$2.25 million in shortfall commitments.

Notice under section 708AA(2)(f) of the Corporations Act

In respect of the Entitlement Offer, the Company advises:

1. the New Shares will be offered without disclosure to investors under Part 6D.2 of the Corporations Act;
2. this notice is being given under section 708AA(2)(f) of the Corporations Act, as modified by the Legislative Instrument;
3. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of the Corporations Act;
4. as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) or 708AA(9) of the Corporations Act, which is required to be set out under section 708AA(7) of the Corporations Act;
5. the issue of New Shares Pursuant to the Entitlement Offer is not expected to have any material effect or consequence on the control of the Company.

Rhythm Biosciences

ACN: 619 459 335
ASX: RHY

Issued Capital

100,750,000 Shares
3,000,000 Options

Australian Registered Office

Level 2, 480 Collins Street
Melbourne VIC 3000
www.rhythmbio.com

Directors

Otto Buttula – Chairman of the Board
Trevor John Lockett – Executive Director
Louis James Panaccio – Non-Executive Director
David John White – Non-Executive Director
Eduardo Vom – Non-Executive Director

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

About Rhythm Biosciences

ASX-listed Rhythm Biosciences is endeavoring to develop and commercialise a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower overall cost to public health administrations. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be equipment agnostic and easily used by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.